Safety and Efficacy of Repeated Administrations of NurOwn® in ALS Patients
Trial details
- Registry ID
- NCT03280056
- Phase
- Phase 3
Drug identity checked against registry records
| Trial | Sponsor | Phase | Status | Primary completion |
|---|---|---|---|---|
| Safety and Efficacy of Repeated Administrations of NurOwn® in ALS PatientsNCT03280056 | Brainstorm-Cell Therapeutics | Phase 3 | Completed | 2020-09-29Actual |
| No regulatory events match this view.This does not mean no FDA events have occurred. |